Blood Res.  2023 Sep;58(3):151-155. 10.5045/br.2023.2023120.

Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report

• Park S
• Shim JR
• Lee JH
• Han JY

• KMID: 2546318
• DOI: http://doi.org/10.5045/br.2023.2023120

Figure

• 

  Fig. 1 (A, B) PBS showing blast cells with occasional sharp and singular Auer rod (Wright-Giemsa stain, ×1,000). (C, D) Bone marrow aspiration smear showing blast cells with bread-like nucleus, salmon-colored granules, and occasional single, long, sharp Auer rods (Wright-Giemsa stain, ×1,000).

• 

  Fig. 2 (A) Agarose gel electro-phoresis of the RT-PCR products showing RUNX1-RUNMX1T1 fusion transcript (size, 197 bp) in lane M4A, and BCR-ABL1 fusion tran-script (size, 320 bp) in M8F lane. (B) Sanger sequencing showing BCR-ABL1, b1a2 (size, 320 bp).

Reference

1. Bloomfield CD, Lawrence D, Byrd JC, et al. 1998; Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58:4173–9. PMID: 9751631.

2. Grimwade D, Walker H, Oliver F, et al. 1998; The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 92:2322–33. DOI: 10.1182/blood.V92.7.2322. PMID: 9746770.

3. Paietta E, Racevskis J, Bennett JM, et al. 1998; Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia. 12:1881–5. DOI: 10.1038/sj.leu.2401229. PMID: 9844918.

4. Soupir CP, Vergilio JA, Dal Cin P, et al. 2007; Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 127:642–50. DOI: 10.1309/B4NVER1AJJ84CTUU. PMID: 17369142.

5. Speck NA, Gilliland DG. 2002; Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2:502–13. DOI: 10.1038/nrc840. PMID: 12094236.

6. Arber DA, Carter NH, Ikle D, Slovak ML. 2003; Value of combined morphologic, cytochemical, and immunophenotypic features in predicting recurrent cytogenetic abnormalities in acute myeloid leukemia. Hum Pathol. 34:479–83. DOI: 10.1016/S0046-8177(03)00085-6. PMID: 12792922.

7. Kelly LM, Gilliland DG. 2002; Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 3:179–98. DOI: 10.1146/annurev.genom.3.032802.115046. PMID: 12194988.

8. Arber DA, Orazi A, Hasserjian R, et al. 2016; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.

9. Bacher U, Haferlach T, Alpermann T, et al. 2011; Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol. 152:713–20. DOI: 10.1111/j.1365-2141.2010.08472.x. PMID: 21275954.

10. Jakovic L, Fekete MD, Virijevic M, et al. 2022; De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1:: RUNX1T1 and BCR::ABL1 (p190 minor transcript). J Hematop. 15:191–5. DOI: 10.1007/s12308-022-00509-4.

11. Gupta R, Mittal N, Rahman K, et al. 2018; Rare BCR-ABL1 transcript in a RUNX1-RUNX1T1-positive de novo acute myeloid leukemia: the chicken and egg tale. Int J Lab Hematol. 40:e24–7. DOI: 10.1111/ijlh.12779.

12. Ammatuna E, Divona M, Curzi P, et al. 2009; Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia. Cancer Genet Cytogenet. 195:189–91. DOI: 10.1016/j.cancergencyto.2009.08.014. PMID: 19963124.

13. Musani R, Chang H. 2021; Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML. Blood. 137:2853. DOI: 10.1182/blood.2021011517. PMID: 34014289.

14. Lundán T, Juvonen V, Mueller MC, et al. 2008; Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica. 93:178–85. DOI: 10.3324/haematol.11910. PMID: 18223279.

15. Ozemri Sag S, Yakut T, Gorukmez O, et al. 2015; Qualitative and quantitative evaluation of the BCR-ABL fusion gene in chronic myelogenous leukemia by flourescence in situ hybridization and molecular genetic methods. Genet Test Mol Biomarkers. 19:584–8. DOI: 10.1089/gtmb.2015.0056. PMID: 26308792.